246 related articles for article (PubMed ID: 30450960)
41. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
Stone RM; Moser B; Sanford B; Schulman P; Kolitz JE; Allen S; Stock W; Galinsky I; Vij R; Marcucci G; Hurd D; Larson RA;
Leuk Res; 2011 Mar; 35(3):329-33. PubMed ID: 20688393
[TBL] [Abstract][Full Text] [Related]
42. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
[TBL] [Abstract][Full Text] [Related]
43. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
Burnett AK; Hills RK; Hunter AE; Milligan D; Kell WJ; Wheatley K; Yin J; McMullin MF; Dignum H; Bowen D; Russell NH;
Leukemia; 2013 Jan; 27(1):75-81. PubMed ID: 22964882
[TBL] [Abstract][Full Text] [Related]
44. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Walter RB; Medeiros BC; Gardner KM; Orlowski KF; Gallegos L; Scott BL; Hendrie PC; Estey EH
Haematologica; 2014 Jan; 99(1):54-9. PubMed ID: 24142996
[TBL] [Abstract][Full Text] [Related]
45. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
Apostolidou E; Cortes J; Tsimberidou A; Estey E; Kantarjian H; Giles FJ
Leuk Res; 2003 Oct; 27(10):887-91. PubMed ID: 12860007
[TBL] [Abstract][Full Text] [Related]
46. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
Borthakur G; Cortes JE; Estey EE; Jabbour E; Faderl S; O'Brien S; Garcia-Manero G; Kadia TM; Wang X; Patel K; Luthra R; Koller C; Brandt M; Ravandi F; Kantarjian H
Am J Hematol; 2014 Oct; 89(10):964-8. PubMed ID: 24990142
[TBL] [Abstract][Full Text] [Related]
47. [CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
Takahashi W; Nakamura Y; Tadokoro J; Handa T; Arai H; Tokita K; Iso H; Tsurumi S; Sasaki K; Maki K; Mitani K
Rinsho Ketsueki; 2012 Jan; 53(1):71-7. PubMed ID: 22374527
[TBL] [Abstract][Full Text] [Related]
48. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
Hütter-Krönke ML; Benner A; Döhner K; Krauter J; Weber D; Moessner M; Köhne CH; Horst HA; Schmidt-Wolf IG; Rummel M; Götze K; Koller E; Petzer AL; Salwender H; Fiedler W; Kirchen H; Haase D; Kremers S; Theobald M; Matzdorff AC; Ganser A; Döhner H; Schlenk RF
Haematologica; 2016 Jul; 101(7):839-45. PubMed ID: 27036160
[TBL] [Abstract][Full Text] [Related]
49. Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Pirrotta MT; Bocchia M; Bucalossi A; Defina M; Forconi F; Gozzetti A; Lauria F
Acta Haematol; 2007; 118(1):7-9. PubMed ID: 17389781
[No Abstract] [Full Text] [Related]
50. Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.
Wang J; Yang YG; Zhou M; Xu JY; Zhang QG; Zhou RF; Chen B; Ouyang J
PLoS One; 2013; 8(4):e60699. PubMed ID: 23593285
[TBL] [Abstract][Full Text] [Related]
51. Treatment strategies in patients with core-binding factor acute myeloid leukemia.
Solis EC
Curr Oncol Rep; 2011 Oct; 13(5):359-60. PubMed ID: 21755276
[TBL] [Abstract][Full Text] [Related]
52. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
[TBL] [Abstract][Full Text] [Related]
53. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
Haematologica; 2015 Sep; 100(9):1172-9. PubMed ID: 26022709
[TBL] [Abstract][Full Text] [Related]
54. Outcome of older patients with acute myeloid leukemia in first relapse.
Sarkozy C; Gardin C; Gachard N; Merabet F; Turlure P; Malfuson JV; Pautas C; Micol JB; Thomas X; Quesnel B; Celli-Lebras K; Preudhomme C; Terré C; Fenaux P; Chevret S; Castaigne S; Dombret H
Am J Hematol; 2013 Sep; 88(9):758-64. PubMed ID: 23749683
[TBL] [Abstract][Full Text] [Related]
55. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
56. Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
Mele A; Sparaventi G; Guiducci B; Nicolini G; d'Adamo F; Leopardi G; Delfini C; Piccaluga P; Visani G
Haematologica; 2004 Jun; 89(6 Suppl):ECR18. PubMed ID: 15194554
[No Abstract] [Full Text] [Related]
57. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
58. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Lambert J; Lambert J; Nibourel O; Pautas C; Hayette S; Cayuela JM; Terré C; Rousselot P; Dombret H; Chevret S; Preudhomme C; Castaigne S; Renneville A
Oncotarget; 2014 Aug; 5(15):6280-8. PubMed ID: 25026287
[TBL] [Abstract][Full Text] [Related]
59. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Serio B; Grimaldi F; Ammirati L; Annunziata M; De Santis G; Perrotta A; De Novellis D; Giudice V; Morini D; Storti G; Califano C; Risitano AM; Pane F; Selleri C
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2044. PubMed ID: 38662362
[TBL] [Abstract][Full Text] [Related]
60. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
